Pliant Therapeutics (PLRX) news
Recent news
Pliant Therapeutics Q2 EPS USD -0.36
AInvest Wire · Aug 11, 2026Pliant Therapeutics 1Q loss/share 32c vs. loss/share 92c y/y
Pliant Therapeutics (NASDAQ: PLRX) reported a first-quarter 2026 net loss per share of $0.32, compared to a loss of $0.92 per share in the same period of 2025, reflecting a significant year-over-year improvement in financial performance. The company’s loss for the quarter totaled $18.7 million,…
AInvest Wire · May 11, 2026ImportantPliant Therapeutics to assemble external expert panel to review data
Pliant Therapeutics to assemble external expert panel to review data Pliant Therapeutics, a late-stage biotechnology company specializing in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, recently announced the upcoming presentation of promising data…
AInvest Wire · Feb 13, 2025ImportantPliant Therapeutics announces next steps in Beacon-IPF trial
Pliant Therapeutics announces next steps in Beacon-IPF trial Pliant Therapeutics (Nasdaq: PLRX), a late-stage biopharmaceutical company specializing in the discovery and development of novel therapies for fibrotic diseases, announced on February 7, 2025, that it had voluntarily paused enrollment…
AInvest Wire · Feb 13, 2025ImportantPliant Therapeutics pauses enrollment in Beacon-IPF trial
Pliant Therapeutics pauses enrollment in Beacon-IPF trial The biopharmaceutical industry has seen its fair share of setbacks, and the latest one comes from Pliant Therapeutics (Nasdaq: PLRX). The company, which specializes in the discovery and development of novel therapeutics for fibrotic…
AInvest Wire · Feb 10, 2025Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.